Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CX-2051 by CytomX Therapeutics for Epithelial Tumor: Likelihood of Approval
CX-2051 is under clinical development by CytomX Therapeutics and currently in Phase I for Epithelial Tumor. According to GlobalData, Phase...
CX-2051 by CytomX Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
CX-2051 is under clinical development by CytomX Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...
CX-2051 by CytomX Therapeutics for Solid Tumor: Likelihood of Approval
CX-2051 is under clinical development by CytomX Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
CX-904 by CytomX Therapeutics for Solid Tumor: Likelihood of Approval
CX-904 is under clinical development by CytomX Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
CX-904 by CytomX Therapeutics for Colorectal Cancer: Likelihood of Approval
CX-904 is under clinical development by CytomX Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
Pacmilimab by CytomX Therapeutics for Small Intestine Cancer: Likelihood of Approval
Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Small Intestine Cancer. According to GlobalData,...
Pacmilimab by CytomX Therapeutics for Salivary Gland Cancer: Likelihood of Approval
Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Salivary Gland Cancer. According to GlobalData,...
CX-904 by CytomX Therapeutics for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
CX-904 is under clinical development by CytomX Therapeutics and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According...
CX-904 by CytomX Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
CX-904 is under clinical development by CytomX Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
CX-904 by CytomX Therapeutics for Esophageal Cancer: Likelihood of Approval
CX-904 is under clinical development by CytomX Therapeutics and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...
CX-904 by CytomX Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
CX-904 is under clinical development by CytomX Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
CX-904 by CytomX Therapeutics for Gastric Cancer: Likelihood of Approval
CX-904 is under clinical development by CytomX Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
Pacmilimab by CytomX Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Pacmilimab by CytomX Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Pacmilimab by CytomX Therapeutics for Metastatic Breast Cancer: Likelihood of Approval
Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...
Pacmilimab by CytomX Therapeutics for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...
Risk adjusted net present value: What is the current valuation of CytomX Therapeutics's CX-2051?
CX-2051 is a monoclonal antibody conjugated commercialized by CytomX Therapeutics, with a leading Phase I program in Metastatic Colorectal Cancer....
Pacmilimab by CytomX Therapeutics for Thymic Carcinoma: Likelihood of Approval
Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase...
CX-2029 by CytomX Therapeutics for Prostate Cancer: Likelihood of Approval
CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...
Pacmilimab by CytomX Therapeutics for Metastatic Breast Cancer: Likelihood of Approval
Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...